Dezima Pharma Raises $18.6 Million For Next-Generation CETP Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.